Sven Turkalj
@SvenTurkalj
Postdoctoral Research Fellow in the Armstrong Lab at the @DanaFarber
🔥Pre-print🔥 We show that therapy-resistant clones are selected within 1-3 cycles of IVO+VEN+/-AZA, months or years before relapse, within rare populations of persistent LSCs. Consistently, in patients with sustained remission, only WT/CH cells persist. biorxiv.org/content/10.110…
Excited to see BoneMarrowMap out in press! Please check out the R package (now capable of classifying 100,000 hematopoietic cells in 10 minutes) and consider giving the paper a read for some insights into how differentiation goes wrong in AML!
Online now concurrent with #AACR25 #hematooncology Minisymposium talk by @andygxzeng and Dr. John Dick team @PMResearch_UHN: Single-cell transcriptional mapping reveals genetic and hierarchy-based determinants of aberrant differentiation in AML. brnw.ch/21wShfF
🔥New Fraticelli lab publication🔥 “Pre-existing stem cell heterogeneity dictates clonal responses to the acquisition of leukemia driver mutations” Two new figures compared to the pre-print, with more in vivo and sequential mutagenesis data. sciencedirect.com/science/articl…
Huge congrats @vshar15!! 🥳👨🎓
I am two days late with this, but congratulations to Vassi Sharlandjieva for successfully defending her thesis! And a big thanks to examiners Brian Huntly and @andiroy ! @MRC_WIMM @MRC_MHU
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy biorxiv.org/cgi/content/sh… #biorxiv_cancer
So excited to present our work this Sunday in San Diego at #ASH2024! Very rapid clonal selection within BM populations known to harbor LSC activity foreshadows clinical outcome following IVO+VEN+/-AZA. A great collaboration between Oxford and the MD Anderson! Abstract 642 👇
🎉Excited to present our latest work out today @Nature 1.What gives a leukemia its phenotype – the oncogenic driver or the differentiation stage of the cell-of-origin? 2.Why do RAS mutations always happen late in AML? 3.Who will relapse after VEN? nature.com/articles/s4158…
What role does epigenetic regulation play in hematopoietic stem cell fate? Drs. Yiran Meng and Claus Nerlov at @MRC_WIMM discuss our current understanding of the field, including chromatin accessibility, DNA methylation, and histone modifications. bit.ly/3B5UEi6
Really pleased to share this clinically important collaborative study between UK AmML Clinical Trial Group and Hovon. The first of many future pan-European collaborative studies in AML and High risk MDS
Read the full study: ascopubs.org/doi/full/10.12…. Special thanks to @pvyas_oxford and Peter Valk for leading this great UK-HOVON joint project. Many thanks to all collaborators to these clinical trials! #HOVON #NCRI. 🧵9/9
NEW: Research from the Nerlov & @vyas_lab in the @MCR_MHU has identified platelet-biased blood stem cells in humans for the first time, showing that this subtype of stem cells is a conserved feature of mammalian evolution. Read more: imm.ox.ac.uk/news/of-mice-a…
🚨New Paper Alert🚨Excited to share our research on human HSC heterogeneity, now published in @SciImmunology! Check out the full paper here: science.org/doi/10.1126/sc…. See some highlights below.
Delighted to share our latest work performed in close collaboration with the Nerlov lab. Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved | Science Immunology science.org/doi/10.1126/sc…
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging dlvr.it/TBN8DX
Check the amazing tweetorial from @asger_jakobsen about our work on DNMT3A and TET2 mutant clonal hematopoiesis! 🧵👇
Mutant HSCs in human clonal haematopoiesis have an attenuated response to inflammation and ageing, which may give them a selective advantage. Happy to share our new paper published in @CellStemCell: doi.org/10.1016/j.stem… A thread below… /1
NEW: Study published in @CellStemCell by @vyas_lab, with the Dick and Xie labs at @pmcancercentre, uncovers key details of clonal outgrowth in blood cells with ageing. Read more: bit.ly/45D3b74 Congrats to @asger_jakobsen, @SvenTurkalj, @pvyas_oxford & all authors!
There is strong selective pressure for CH mutations in #HSC, as a way to attenuate the impact of inflammation and aging. Such a wonderful collaboration with @pvyas_oxford and John Dick, driven by @asger_jakobsen @SvenTurkalj @andygxzeng. @MRC_WIMM @PMResearch_UHN
Excited to share: Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging: Cell Stem Cell cell.com/cell-stem-cell… Huge privilege to work colleagues in the lab and with Andy, Stephanie and John
Stem cell competition in human bone marrow. New study in @CellStemCell has found that resistance to inflammation gives mutated blood stem cells in human bone marrow a growth advantage over non-mutated stem cells. doi.org/10.1016/j.stem… @stephxie @UHN_research @pvyas_oxford